Regulator of Chromosome Condensation Found as Cancer Drug Target

Target Name: RCC1

NCBI ID: G1104

RCC1

Regulator of Chromosome Condensation Found as Cancer Drug Target

Regulator of Chromosome Condensation (RCC1) is a protein that plays a crucial role in the regulation of chromosome condensation, which is the process by which chromosomes are coiled together in the nucleus of a cell. RCC1 is a key regulator of the condensation process, and its dysfunction has been implicated in a number of diseases, including cancer. As a result, RCC1 has become a drug target and a focus of research in the field of genetics.

The condensation of chromosomes is a critical process that occurs in the nucleus of a cell. During cell division, the chromosomes are replicated, then divided equally between the two daughter cells. In addition, the condensation of chromosomes helps to ensure the proper separation of chromosomes during cell division and reduces the risk of genetic abnormalities that can occur if the chromosomes are not properly separate.

RCC1 is a protein that was identified as a key regulator of chromosome condensation. It is a small non-coding RNA molecule that is expressed in high levels in the nucleus of a cell. RCC1 functions by interacting with the histone proteins that make up the chromosomes. It helps to recruit histone-associated proteins to the chromatin and thereby regulates the condensation of chromosomes.

In addition to its role in regulating chromosome condensation, RCC1 has also been shown to play a role in the regulation of gene expression. It has been shown to interact with the transcription factors that control the expression of genes, and to regulate the levels of their products in the cell. This suggests that RCC1 may be a useful target for drugs that are aimed at modulating gene expression.

The failure of RCC1 to function properly can have serious consequences for the health of a cell. In diseases such as cancer, RCC1 dysfunction is often observed, which can lead to the development of chromosomal abnormalities and the risk of genetic abnormalities. As a result, targeting RCC1 has become a focus of research in the field of cancer.

One approach to targeting RCC1 is to use drugs that specifically interact with it. These drugs can be used to inhibit the activity of RCC1, which would help to reduce the level of chromosomal condensation and the risk of genetic abnormalities. One class of drugs that have been shown to interact with RCC1 are the small molecules that have been shown to inhibit the activity of histone-associated proteins. These drugs have been shown to be effective in a variety of cancer therapies.

Another approach to targeting RCC1 is to use antibodies that are designed to target specific regions of the protein. These antibodies can be used to specifically block the activity of RCC1, which would help to reduce the level of chromosomal condensation and the risk of genetic abnormalities. One class of antibodies that have been shown to be effective in this regard are the monoclonal antibodies that are produced by cell-based assays. These antibodies can be easily modified and are highly specific, making them an attractive option for targeting RCC1.

In addition to its potential as a drug target, RCC1 is also of interest as a biomarker for the diagnosis and prognosis of cancer. The levels of RCC1 have been shown to be elevated in a variety of cancer types, including breast, ovarian, and colorectal cancers. Additionally, RCC1 has been shown to be associated with poor prognosis in patients with cancer.

Given the potential benefits of targeting RCC1, there is a growing interest in developing drugs that can inhibit its activity. These drugs can be used to treat a variety of cancer types, including breast, ovarian, and colorectal cancers. In addition, RCC1 has also

Protein Name: Regulator Of Chromosome Condensation 1

Functions: Guanine-nucleotide releasing factor that promotes the exchange of Ran-bound GDP by GTP, and thereby plays an important role in RAN-mediated functions in nuclear import and mitosis (PubMed:1944575, PubMed:17435751, PubMed:20668449, PubMed:22215983, PubMed:11336674). Contributes to the generation of high levels of chromosome-associated, GTP-bound RAN, which is important for mitotic spindle assembly and normal progress through mitosis (PubMed:12194828, PubMed:17435751, PubMed:22215983). Via its role in maintaining high levels of GTP-bound RAN in the nucleus, contributes to the release of cargo proteins from importins after nuclear import (PubMed:22215983). Involved in the regulation of onset of chromosome condensation in the S phase (PubMed:3678831). Binds both to the nucleosomes and double-stranded DNA (PubMed:17435751, PubMed:18762580)

The "RCC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RCC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets